Dr Juan Carlos Castillo presents a study on the use of corifollitropin alfa in double ovarian stimulation cycles at Fertility 2024.

In the framework of the Annual Fertility Conference, held from 10 to 13 January 2024 at the Edinburgh International Congress Centre, Dr Juan Carlos Castillo, Instituto Bernabeu’s Scientific Director, participated with an oral presentation of his study on the use of corifollitropin alfa in DuoStim cycles.

On Saturday, January 13^th, Dr Castillo gave a lecture detailing the findings of his research entitled “Exploring uninterrupted corifollitropin alfa use in DuoStim cycles: A proof-of-concept study for improved efficiency and patient convenience in ovarian stimulation”.

Corifollitropin alfa is a hormone used for ovarian stimulation in fertility treatments. The innovation lies in its uninterrupted use in DuoStim cycles, a technique involving ovarian stimulation in two phases within a single menstrual cycle. “Our aim was to explore the feasibility and benefits of using corifollitropin alfa uninterrupted in DuoStim cycles. The results are promising and suggest that this approach could significantly improve the efficiency of the process providing greater convenience for patients,” he said.

The potential benefits for assisted reproduction treatment patients are notable: minimising the stress and burden of treatment and decreasing the possibility of error in medication administration and management, thus offering patients a more personalised experience tailored to their individual needs.